HR 5547 United States House · 118th Congress

Maintaining Investments in New Innovation Act

The Maintaining Investments in New Innovation Act (HR 5547) extends the exclusivity period for certain advanced drugs from 7 to 11 years. It defines an "advanced drug product" as a drug using genetically targeted technology to change how genes work, such as drugs that suppress or activate gene function. The bill amends the Social Security Act to update the definition of "qualifying single source drug" to include these advanced therapies with the longer exclusivity period. This change directly affects drug manufacturers developing such advanced therapies and influences Medicare's drug coverage rules by delaying generic competition for these specific treatments.

Issues: ✓ Healthcare

Sub-Topics: Medicare

Bill status in committee 1 of 4 stages cleared

Introduction

Sep 2023

Committee Review

Floor Vote

President

Introduced Sep 18, 2023 Last action Dec 17, 2024

Floor votes

How they voted

No floor votes recorded yet.

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Dec 17, 2024

Committee

Referred to the Subcommittee on Health.

lower

Sep 22, 2023

Committee

Referred to the Subcommittee on Health.

lower

Sep 18, 2023

Committee

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

lower

Sep 18, 2023

Introduced

Introduced in House

lower

1 primary · 28 co-sponsors